Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.74 |
| ▸ | CTSK | P43235 | 6/20 | 0.74 |
| ▸ | CTSB | P07858 | 4/20 | 0.74 |
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758057 | 1.00 | CTSS (0.74) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL2333358 | 1.00 | CTSS (0.74) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL30655726 | 1.00 | CTSS (0.74) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL1073538 | 1.00 | CTSS (0.74) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL30829402 | 1.00 | CTSS (0.74) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL20905314 | 0.90 | CTSS (0.71) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL27350854 | 0.90 | CTSS (0.71) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL30578593 | 0.89 | CTSS (0.69) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL29657242 | 0.89 | CTSS (0.69) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL2346583 | 0.89 | CTSS (0.69) | CTSSCTSKCTSBACECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2026-02-05 | — | — | US | disclosed |
| CN-118702627-A | CD73 small molecule inhibitor, pharmaceutical composition and application thereof | 深圳市新樾生物科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-3914256-B1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| US-20240049709-A1 | METHOD OF CONTROLLING FUNGAL INFECTIONS IN PLANTS | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION, (A.R.O), THE VOLCANI INSTITUTE (IL) | 2024-02-15 | — | — | US | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-110869352-B | Chemical compound | 诺瑟拉有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1490371-A4 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6933294-B2 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-1490371-A1 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058930-A1 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-25 | — | — | US | disclosed |
| WO-2003084959-A1 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058930-A1 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | ABCG2, PFAS, CYP2F1 | CTSS 461/4885CTSK 535/4885CTSB 890/4885 |
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | PLA2G2F, PLA2R1, PLA2G12A | CTSS 485/4885CTSK 594/4885CTSB 420/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | CTSS 2311/4885CTSK 1687/4885CTSB 2510/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | CTSS 338/4885CTSK 712/4885CTSB 303/4885 |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | CTSS 1245/4885CTSK 1722/4885CTSB 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.